Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic Dermatitis (Pilot RCT)

March 4, 2026 updated by: Institute of Dermatology, Thailand

A Prospective, Randomized, Split-Face Pilot Study Comparing the Efficacy of the Institute of Dermatology's Antioxidant Moisturizing Serum in Mild to Moderate Seborrheic Dermatitis

This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. The process of subject recruitment and clinical data collection will take place at the Outpatient Department (OPD) while photograph taking and skin measurement will take place at Laser Center and Bioengineering Department, respectively. All bioengineering instruments will be operated under the climate controlled environment; i.e, at temperature 20+/-2 degree Celsius and 50+/-2 % of relative humidity. A subject must get acclimatized to the ambient atmosphere for at least 30 minutes. The clinical data, skin barrier function, the quality of life, subject's satisfaction scale will be collected at the first day (D0, as baseline) and 4th week after finishing the test product (Wk4).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Veng Ang Lok, Medical Doctor
  • Phone Number: +66839392488, +85598988089
  • Email: lokvengang@gmail.com

Study Contact Backup

  • Name: Walaiorn Pratchyapruit, Medical Doctor
  • Phone Number: +66 958784022
  • Email: Itesatuk@yahoo.com

Study Locations

  • Thailand
    • Bangkok
      • Ratchathewi, Bangkok, Thailand, 10400
        • Recruiting
        • Institute of dermatology
        • Contact:
        • Principal Investigator:
          • Veng Ang Lok, Medical Doctor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Age: ≥ 18 years old
  • Gender: Male and Female
  • Patient who never uses or has stopped using topical corticosteroids/calcineurin inhibitor or other topical treatments exerting anti-inflammatory action (on the face) more than 2 weeks before entering this clinical trials.
  • Patient who does not use cosmetic containing any oxidants or others that exert anti-oxidant effect(s). If there is any, one must refrain from using them more than 2 weeks before entering this clinical trials.

Exclusion Criteria

  • Patients with known cases of underlying HIV/AIDS, neurological condition e.g., Parkinson's disease.
  • Patient associated with any autoimmune diseases and other skin diseases
  • Patient takes any forms of oral immunotherapy more than 2 months up to the first day of clinical trials.
  • Patients continuously use of topical corticosteroids or other anti-inflammatory medicines on regular basis up to the first day of clinical trial.
  • Patient who refuses to stop using cosmetic(s) containing anti-oxidants or those exert anti-oxidant effect(s).
  • Patient who is allergic to the test product or one of its ingredients.
  • Pregnancy or nursing woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Other: Antioxidant moisturizing serum
Antioxidant Moisturizing Serum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SEDASI score
Time Frame: 1 year
To compare clinical improvement as assessed by SEDASI score, between the intervention and control sides of the face in subjects with mild to moderate seborrheic dermatitis after 4 weeks of application of Institute of Dermatology's antioxidant moisturizing serum. This study uses split-face design. Due to the split-face study design and use of the SEDASI score, the same scoring scales were applied for extension (area, 0-6), presentation pattern (0-3), erythema (0-3), and scaling (0-3). The nasal area was excluded because split application to the nose is impractical. The original severity classification was therefore divided by two to obtain a hemiface-specific severity classification. Note: As the nasal area represents approximately 1% of the facial surface and the study compares the two sides of the face, this modification does not affect the primary study objective. The total score may range from 0 (no Seborrheic Dermatitis) to 30 (Seborrheic Dermatitis of the worst possible degree).
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Barrier function
Time Frame: 4 weeks

To evaluate skin barrier function, as measured by transepidermal water loss (TEWL) and skin hydration, and surface lipid after 4 weeks of using IOD's antioxidant moisturizing serum.

To evaluate facial skin appearance-including glossiness, desquamation, roughness, smoothness, wrinkles, elasticity, and redness-after 4 weeks of using IOD's antioxidant moisturizing serum.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institute of Dermatology, Thailand

Investigators

  • Principal Investigator: Veng Ang Lok, Medical Doctor, Rangsit University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 20, 2026

Primary Completion (Estimated)

May 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

February 19, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 25, 2026

Study Record Updates

Last Update Posted (Actual)

March 6, 2026

Last Update Submitted That Met QC Criteria

March 4, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 026/2568

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We are not allowed to share IPD without participants' permission in advance.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Seborrheic Dermatitis on the Face

Clinical Trials on Antioxidant moisturizing serum

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe